Journal of Clinical InvestigationCancer BiologyPeer-reviewed journal article
NF2 loss malignantly transforms human pancreatic acinar cells and enhances cell fitness under environmental stress
Yi XuiD, Michael H Nipper, Angel A. Dominguez, Chenhui He, Francis E. SharkeyiD, Sajid Khan, Han XuiD, Daohong ZhouiD, Lei Zheng, Yu LuaniD, Jun Liu, Pei WangiD
Abstract
Pancreatic ductal adenocarcinoma (PDAC) occurs as a complex, multifaceted event driven by the interplay of tumor permissive genetic mutations, nature of cellular origin and microenvironmental stress. In this study, using primary human pancreatic acinar 3D organoids, we performed CRISPR knockout screen targeting 199 previously underappreciated potential tumor suppressors curated from clinical PDAC samples. Our data revealed significant enrichment of a list of candidates, with NF2 emerging as the top target. Functional validation confirmed that loss of NF2 promotes the transition of PDAC to an invasive state, potentially through extracellular matrix modulation. NF2 inactivation was found to enhance PDAC cell fitness under nutrient starvation. This adaptation not only reinforces the oncogenic state but also confers therapeutical resistance. Additionally, we found that NF2 loss is associated with the fibroblast heterogeneity and cancer-stroma communications in tumor evolution. These findings establish NF2 as a critical tumor suppressor in PDAC and uncover its role in mediating nutrient adaptation and drug resistance. Importantly, this study provides new insights into drug resistance mechanisms and potential therapeutic targets in PDAC.
- organism: human
- assay: organoid / primary culture
- research focus: cancer & tumor microenvironment
- approach: genetic perturbation / CRISPR
- Citations
- 5
- FWCI
- 14.65
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- c-Rel drives pancreatic cancer metastasis through Fibronectin-Integrin signaling-induced isolation stress resistance and EMT activation
D. Bakırdöğen, Kıvanç Görgülü, … Hana Algül·Molecular CancerPeer-reviewed·Dec 15, 2025
- Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition
Ryne C. Ramaker, Andrew A. Hardigan, … Sara J. Cooper·bioRxiv·Oct 27, 2020
- Tumor nutrient stress gives rise to a drug tolerant cell state in pancreatic cancer
Colin S. Sheehan, Lyndon Hu, … Alexander Muir·bioRxiv·Sep 4, 2025
- Adaptation to an acid microenvironment promotes pancreatic cancer organoid growth and drug resistance in a p53-dependent manner
A. Stigliani, R. Ialchina, … A. Sandelin·bioRxiv·Jan 2, 2023
- PP2A activation drives aberrant macropinocytosis and cell death in pancreatic ductal adenocarcinoma
Garima Baral, Claire M. Pfeffer, … Brittany L. Allen-Petersen·bioRxiv·Jul 14, 2025
- Tumor cell-intrinsic stress states drive sensitivity to CAR T cell-therapy in pancreatic cancer
Julia Fröse, Evelyn Chen, … Michael T. Hemann·Science AdvancesPeer-reviewed·Oct 2, 2026